ClinicalTrials.gg
CompletedNCT01485445Updated Jun 12, 2017

Bioequivalence Study to Compare Fluticasone Furoate (FF) 1-strip Inhaler With FF 2-strip Inhaler and With FF/Vilanterol Combination

A Phase 1 interventional study of Fluticasone Furoate (200mcg unit strength) and Fluticasone Furoate/Vilanterol (200/25mcg unit strength) in Asthma, sponsored by GlaxoSmithKline. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-12.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
28th of 40
30 · median 102
Started
2011
with 3 others
Phase 1
8 of 40
none open now
Registered
21st of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one is the 28th largest by enrollment, is one of 4 that started in 2011, is one of 8 in phase 1, and was the 21st registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

The purpose of this study is to determine the bioequivalence of fluticasone furoate (FF) inhalation powder (single strip configuration) compared with FF inhalation powder (two strip configuration) and compared with FF / vilanterol (VI) inhalation powder. Fluticasone furoate (FF), is being developed both as a monotherapy for the treatment of asthma and in combination with vilanterol (VI) for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). Thirty healthy male and female subjects will be enrolled in the study to ensure twenty-four evaluable subjects.

Read the detailed description

Fluticasone furoate (FF; GW685698), a novel corticosteroid, is being developed both as a monotherapy for the treatment of asthma and in combination with vilanterol (VI; GW642444) for the treatment of asthma and COPD. The novel dry powder inhaler (NDPI) will be used to deliver both FF monotherapy and the FF/VI combination. The NDPI can be used with either a single strip or two strips, the single strip being used for FF monotherapy and two strips being used to deliver the FF/VI combination. In some previous FF monotherapy studies, including the phase IIB programme, conducted using the NDPI, the inhaler contained two strips (FF in the first strip and matched VI placebo in the second strip). This two strip configuration has been used for the majority of FF monotherapy treatment arms in previous and ongoing studies. The aim of this study is to determine the bioequivalence of FF monotherapy (single strip) compared with FF monotherapy (two strip), and to determine the bioequivalence of FF monotherapy (single strip) compared with FF/VI, administered via the NDPI. This data will facilitate the inclusion of FF monotherapy (two strip) data and FF/VI combination data to support the FF monotherapy product development. This will be a randomised, open-label, replicate, six-way crossover, single dose study in healthy male and female subjects. Thirty healthy male and female subjects will be enrolled in this study to ensure twenty-four evaluable subjects.

Pharmacokinetic samples will be taken over 36 hours. Safety will be assessed by adverse event (AE) monitoring throughout the study.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • bioequivalence
  • pharmacokinetics
  • Fluticasone Furoate
  • Vilanterol
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • Male or female between 18 and 65 years of age inclusive, at the time of signing the .
  • A female subject is eligible to participate if she is of:

Non- defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or defined as 12 months of spontaneous amenorrhea Child-bearing potential and agrees to use one of the methods listed in Section 8.1 of the protocol for an appropriate period of time prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until completion of the follow-up visit.

  • (BMI) within the range 18.5-29.0 kg/m2 (inclusive).
  • (AST), alanine aminotransferase (ALT), alkaline phosphatase and are less than or equal to 1.5x (ULN) (isolated bilirubin greater than 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin is less than 35%).
  • Average less than 450 msec.
  • (FEV1) greater than or equal to 85% predicted at screening.
  • Subjects who are current non-smokers, who have not used any tobacco products in the 12 month period preceding the screening visit, and have a pack history of less than or equal to 5 pack years (number of pack years = (number of cigarettes per day/20) x number of years smoked)
  • Able to satisfactorily use the novel dry powder inhaler (NDPI)
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. Subjects must have signed the Informed Consent Form (ICF) prior to the commencement of any screening activities.

Exclusion criteria

Exclusion Criteria:

  • As a result of medical interview, physical examination or screening investigations, the principal investigator or delegate physician deems the subject unsuitable for the study. Subjects must not have a systolic blood pressure above 140 mmHg or a diastolic pressure above 90 mmHg.
  • The subject has a history of breathing problems in adult life (e.g. history of asthmatic symptomatology). Screening lung function tests () will be performed to confirm normal lung function parameters (greater than or equal to 85% predicted).
  • Subjects who have suffered a lower respiratory tract infection within 4 weeks of the screening visit.
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • The subject has been treated for or diagnosed with depression within six months of screening or has a history of significant psychiatric illness.
  • A positive pre-study surface antigen or positive antibody result within 3 months of screening
  • A positive test for (HIV) antibody.
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of greater than 21 units for males or greater than 14 units for females.
  • A positive pre-study drug/alcohol screen or when randomly tested during the study.
  • Positive cotinine and urine alcohol test at screening or on admission to the Unit.
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • The subject has taken systemic, oral or depot less than 12 weeks before the screening visit.
  • The subject has taken inhaled, intranasal or topical steroids less than 4 weeks before the screening visit.
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
  • History of sensitivity to any of the study medications, including immediate or delayed to any beta-agonist, sympathomimetic drug, or any intranasal, inhaled or systemic corticosteroid therapy; known or suspected sensitivity to the constituents of the new powder inhaler (i.e. lactose or magnesium stearate), or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates participation.
  • History of severe milk protein allergy.
  • Consumption of red wine, seville oranges, grapefruit or grapefruit juice pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 30 day period.
  • Pregnant females as determined by positive serum hCG test at screening or by positive serum/urine hCG test prior to dosing.
  • Lactating females.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • Subject is mentally or legally incapacitated.
  • Vulnerable subjects (eg kept in detention) or Parexel / GSK employees
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Fluticasone Furoate (single strip configuration)

    400mcg, administered as 2 inhalations of 200mcg

    Drug: Fluticasone Furoate (200mcg unit strength)

  • Experimental
    Fluticasone Furoate (two strip configuration)

    400mcg, administered as 2 inhalations of 200mcg. Second strip contains lactose and magnesium stearate

    Drug: Fluticasone Furoate (200mcg unit strength)

  • Experimental
    Fluticasone Furoate/Vilanterol

    400/50mcg, administered as 2 inhalations of 200/25mcg

    Drug: Fluticasone Furoate/Vilanterol (200/25mcg unit strength)

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameters for Fluticasone Furoate (FF) for all study participants

    Measurement of amount of FF in the blood of study participants. From the plasma concentration-time data the following PK parameters will be determined as data permits: Area Under Curve from pre-dose to infinite time (AUC)(0-inf), Area Under Curve from pre-dose to time of last quantifiable concentration (AUC)(0-t), maximum plasma concentration (Cmax)

    Time frame: 15 time points between pre-dose and 36 hours post-dose in each of the six treatment periods

Secondary outcomes

  1. Pharmacokinetic parameters for Fluticasone Furoate (FF) for all study participants

    Measurement of amount of FF in the blood of study participants. From the plasma concentration-time data the following PK parameters will be determined as data permits: time to maximum plasma concentration (tmax), half-life (t1/2)

    Time frame: 15 time points between pre-dose and 36 hours post-dose in each of the six treatment periods

  2. Adverse events (AEs) for all study participants

    Measurement of types of AEs reported, severity and relationship to study drug

    Time frame: From the start of first dosing until follow-up (approximately 7 weeks per subject)

07

Study locations

1 site
  • GSK Investigational Site
    Berlin, 14050, Germany
08

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2011 to primary completion in Mar 2012, 2 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 2 months is below that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2011
First posted
Dec 5, 2011
StartActual
Dec 21, 2011
Primary completionActual
Mar 12, 2012
CompletionActual
Mar 12, 2012
Last update
Jun 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01485445
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 5, 2011
Start date
Dec 21, 2011
Primary completion
Mar 12, 2012
Completion
Mar 12, 2012
Last update
Jun 12, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone furoate · Vilanterol

Start the discussion